Global Monoclonal Antibodies Market: Overview
Antibodies, which are proteins generated by plasma cells in response to specific antigens, is used for diagnostic and therapeutic purposes. Monoclonal antibodies (mAbs), a type of mono-specific antibodies, are comprised of identical antibody molecules and are produced by a single clone of cells or cell line. Monoclonal antibodies have brought about a fundamental change in pharmaceutical and biotechnology sectors and in the future too are slated to play a crucial role in clinical protocol with further development of these molecular agents. Monoclonal antibodies find application in the treatment of a variety of diseases, particularly autoimmune, cancer, and inflammatory diseases.
The global monoclonal antibodies market is characterized by the presence of numerous global and regional players and is dynamic in nature. The well-entrenched players compete with the local ones on the basis of technology, cost, and product differentiation. Buying into the promise of robust growth in the future, more players will likely try and foray into the market. However, strict guidelines surrounding the manufacture of mAbs may act as a deterrent.
The report provides a detailed analysis of the opportunities and trends in the global monoclonal antibodies market. It segments the global market based on different parameters in order to study them in depth with expert inputs from industry veterans. The report provides a detailed assessment of the prevailing vendor landscape. It also profiles the leading players operating in the market and leveraging industry-leading analytical tools, gauges the threats and opportunities that these companies may face over the course of the forecast period between 2016 and 2024.
Global Monoclonal Antibodies Market: Trends and Opportunities
Driving the growth of the global monoclonal antibodies market is the increasing prevalence of cancer and other chronic diseases. Such maladies have resulted in soaring demand for biologics, which in turn is leading to the demand for monoclonal antibodies. Rising thrust on research and development activities in genomics alongside the emergence of technologically advanced genetic platforms, such as next generation sequencing, have also majorly contributed to the market. In addition, the affordability of the technology needed for research to develop mAbs has also contributed to the growth in the market.
Other factors positively impacting the market are rising awareness among patients and physicians regarding applications of mAb therapy, unveiling of better products every now and then, growing adoption of therapeutic antibodies in cost-sensitive markets, and quick approval by regulatory authorities for breakthrough therapies. Going forward, swift approvals of blockbuster mAbs for different indications, is further slated to up their usage. For example, popular drugs such as Herceptin, Avastin, Rituxan, and Remicade on the back of FDA approval for treating Crohn's disease, cancer, rheumatoid arthritis, ulcerative colitis, etc. would further boost the market.
One drawback of drugs formulated from mAbs is that they are very specific in nature and have limited targets. This is because they just interact with cells and do not penetrate them. This to some extent has hampered the global monoclonal antibodies market. Another difficulty in using mAbs is that they need to be injected unlike small molecule drugs.
Global Monoclonal Antibodies Market: Regional Outlook
Geographically, the global market for monoclonal antibodies can be segmented into Europe, North America, Asia Pacific, and the Rest of the World. Among them, North America holds a dominant position in the market on account of the presence of well-established healthcare infrastructure, increased emphasis by the government for infection control and management, and increasing prevalence of lifestyle-related diseases. In the near future, the market will continue on its upward trajectory due increased funding by the government for cancer research and technology development.
Going forward, Asia Pacific is also predicted exhibit considerable growth owing to rising spending power of the people in the region along with increasing spend on research and development and growing patient awareness pertaining to the therapeutic use of mAbs. By dint of being underpenetrated too, the Asia Pacific market holds out a promise of robust growth.
Companies Mentioned in Report
To present an in-depth assessment of the competition prevailing in the market, the report profiles companies such as Roche, Eli Lilly, Genentech, Pfizer, and Biogen Idec. The report not just profiles such leading players, but also brings to the fore their strengths and weaknesses.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.